The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
MDMA and MDMA-Assisted Therapy
Abstract
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Unlike other psychedelics, MDMA uniquely induces prosocial subjective effects of heightened trust and self-compassion while maintaining ego functioning as well as cognitive and perceptual lucidity. While recreational use in nonmedical settings may still cause harm, especially due to adulterants or when used without proper precautions, conclusions that can be drawn from studies of recreational use are limited by many confounds. This especially limits the extent to which evidence related to recreational use can be extrapolated to therapeutic use. A considerable body of preliminary evidence suggests that MDMA-AT delivered in a controlled clinical setting is a safe and efficacious treatment for PTSD. After a course of MDMA-AT involving three MDMA administrations supported by psychotherapy, 67%-71% of individuals with PTSD no longer meet diagnostic criteria after MDMA-AT versus 32%-48% with placebo-assisted therapy, and effects endure at long-term follow-up. This review primarily aims to distinguish evidence of recreational use in nonclinical settings versus MDMA-AT using pharmaceutical-grade MDMA in controlled clinical settings. This review further describes the putative neurobiological mechanisms of MDMA underlying its therapeutic effects, the clinical evidence of MDMA-AT, considerations at the level of public health and policy, and future research directions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This neurochemical profile contributes to its prosocial effects, including heightened emotional openness and trust, reduced fear responses, and increased receptivity to social connection, all while generally preserving cognitive clarity and perceptual stability (1).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [1]
In the citing paper
“Emerging research supports the safety and efficacy of psychedelic-assisted therapy (PAT) when administered in a controlled clinical environment (1, 2) for several treatment-resistant psychiatric disorders including depression (3–5), post-traumatic stress disorder (PTSD) (6, 7), substance use disorders (8, 9), social anxiety (10), and obsessive-compulsive disorder (11).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [1]
Citations
Cites
4 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359
RetractedRicaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2002) · Science · doi:10.1126/science.1074501 · Cited by 179
RetractedJerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05548-2 · Cited by 159
RetractedRicaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2003) · Science · doi:10.1126/science.301.5639.1479b · Cited by 65
RetractedPosttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Research works printed but not linked: 18
- Greer G, 1985, Advances, 2, 57
- Young FL, 1986, In the Matter of MDMA Scheduling, Docket No 84-48, Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of Administrative Law Judge on Issues Two through Seven
- 10.1038/sj.npp.1395197 · DOI · Paper page
- Connolly E, 1999, Crit Care Resusc, 1, 368
- Battaglia G, 1987, J Pharmacol Exp Ther, 242, 911
- Vollenweider F, 2000, Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans
- Stolaroff M, 2004, The Secret Chief Revealed: Conversations with Leo Zeff
- Multidisciplinary Association for Psychedelic Studies, 2021, MDMA Investigator’s Brochure (MDMA)
- Baggott MJ, 2016, Adv Pharmacol Sci, 2016, 2175896
- Mas M, 1999, J Pharmacol Exp Ther, 290, 136
- Baggott M, Jerome L, Stuart R: 3,4-methylenedioxymethamphetamine (MDMA): a review of the english-language scientific and medical literature 2001
- Parrott AC, 2000, Drug Alcohol Depend, 60, 105
- Potash MN, 2009, Psychiatry (Edgmont), 6, 40
- Volpi-Abadie J, 2013, Ochsner J, 13, 533
- Malberg JE, 1996, J Pharmacol Exp Ther, 278, 258
- Adamson S, 2012, Through the Gateway of the Heart: Accounts and Experiences with MDMA and Other Empathogenic Substances
- VA/DoD Clinical Practice Guidelines, 2023, Management of Posttraumatic Stress Disorder and Acute Stress Disorder
- Itzhaky L, 2014, J depress anxiety, 3, 1
Cited by
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
Muthukumaraswamy, S. D., Baggott, M. J., Schenberg, E. E., Repantis, D., Wolff, M., Forsyth, A., & Noorani, T. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251381074 · Cited by 20
Malhi, G. S., Bell, E., Stavdal, A., Wu, C., Naylor, A., & Kumari, V. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00201-1 · Cited by 22
Askariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111461 · Cited by 15
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Nadeem, Z., Parker, S., McGovern, H. T., Sebben, B., & Oestreich, L. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251346679 · Cited by 9
Metadata
- Authors
- Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B.
- Affiliations
- University of Minnesota (US)
- Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2025-01-01
- Volume
- 182
- Issue
- 1
- Pages
- 79-103
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4405977949
- Cited by
- 62
- References
- 169
- Citations by year
- 2026: 34 · 2025: 27
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA, MDMA-assisted psychotherapy, ecstasy, post-traumatic stress disorder, psychedelic therapy, recreational drug use, drug adulteration, prosocial effects, neurobiological mechanisms, treatment efficacy, public health policy
- MeSH terms
- Hallucinogens, Humans, Psychotherapy, Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDMA and MDMA-Assisted Therapy. https://app.cochat.ai/papers/10.1176/appi.ajp.20230681
- The paper
- Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025). MDMA and MDMA-Assisted Therapy. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.